{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:12:52Z","timestamp":1784128372074,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141114"],"award-info":[{"award-number":["82141114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972339"],"award-info":[{"award-number":["81972339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201616"],"award-info":[{"award-number":["82201616"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000749"],"award-info":[{"award-number":["82000749"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Collaborative Innovation Center for Translational Medicine","award":["TM202102"],"award-info":[{"award-number":["TM202102"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["National Research Center for Translational Medicine"],"award-info":[{"award-number":["National Research Center for Translational Medicine"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["22Y11904700"],"award-info":[{"award-number":["22Y11904700"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Fund from Shanghai Municipal Health Commission","award":["20224Y0027"],"award-info":[{"award-number":["20224Y0027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to identify the druggable cell-intrinsic vulnerabilities and target-based drug therapies for PitNETs using the high-throughput drug screening (HTS) and genomic sequencing methods. We examined 9 patient-derived PitNET primary cells in HTS. Based on the screening results, the potential target genes were analyzed with genomic sequencing from a total of 180 PitNETs. We identified and verified one of the most potentially effective drugs, which targeted the Histone deacetylases (HDACs) both in in vitro and in vivo PitNET models. Further RNA sequencing revealed underlying molecular mechanisms following treatment with the representative HDACs inhibitor, Panobinostat. The HTS generated a total of 20,736 single-agent dose responses which were enriched among multiple inhibitors for various oncogenic targets, including HDACs, PI3K, mTOR, and proteasome. Among these drugs, HDAC inhibitors (HDACIs) were, on average, the most potent drug class. Further studies using in vitro, in vivo, and isolated PitNET primary cell models validated HDACIs, especially Panobinostat, as a promising therapeutic agent. Transcriptional surveys revealed substantial alterations to the Nrf2 signaling following Panobinostat treatment. Moreover, Nrf2 is highly expressed in PitNETs. The combination of Panobinostat and Nrf2 inhibitor ML385 had a synergistic effect on PitNET suppression. The current study revealed a class of effective anti-PitNET drugs, HDACIs, based on the HTS and genomic sequencing. One of the representative compounds, Panobinostat, may be a potential drug for PitNET treatment via Nrf2-mediated redox modulation. Combination of Panobinostat and ML385 further enhance the effectiveness for PitNET treatment.<\/jats:p>","DOI":"10.1186\/s40478-024-01775-2","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:20:47Z","timestamp":1713435647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors"],"prefix":"10.1186","volume":"12","author":[{"given":"Yijun","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0650-2194","authenticated-orcid":false,"given":"Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1611-8228","authenticated-orcid":false,"given":"Zhe Bao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"10","key":"1775_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382(10):937\u2013950","journal-title":"N Engl J Med"},{"issue":"5","key":"1775_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5):516\u2013524","journal-title":"JAMA"},{"key":"1775_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fendo.2019.00007","volume":"10","author":"Q Yang","year":"2019","unstructured":"Yang Q, Li X (2019) Molecular network basis of invasive pituitary adenoma: a review. Front Endocrinol (Lausanne) 10:7","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1775_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1055\/a-1066-4592","volume":"52","author":"ML Gheorghiu","year":"2020","unstructured":"Gheorghiu ML, Negreanu F, Fleseriu M (2020) Updates in the medical treatment of pituitary adenomas. Horm Metab Res 52(1):8\u201324","journal-title":"Horm Metab Res"},{"key":"1775_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:42\u201350","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A et al (2019) Acromegaly. Nat Rev Dis Primers 5(1):20","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1775_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","volume":"138","author":"Z Wang","year":"2009","unstructured":"Wang Z, Zang C, Cui K et al (2009) Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138(5):1019\u20131031","journal-title":"Cell"},{"issue":"1","key":"1775_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Zhang C, Hassan S et al (2018) Histone deacetylase 6 in cancer. J Hematol Oncol 11(1):111","journal-title":"J Hematol Oncol"},{"key":"1775_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.phrs.2016.11.020","volume":"117","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Moreau P, Laubach JP et al (2017) Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacol Res 117:185\u2013191","journal-title":"Pharmacol Res"},{"issue":"3","key":"1775_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/molecules27030715","volume":"27","author":"M Dasko","year":"2022","unstructured":"Dasko M, de Pascual-Teresa B, Ortin I et al (2022) HDAC inhibitors: innovative strategies for their design and applications. Molecules 27(3):715","journal-title":"Molecules"},{"issue":"8","key":"1775_CR11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/neuonc\/noac053","volume":"24","author":"H Yao","year":"2022","unstructured":"Yao H, Xie W, Dai Y et al (2022) TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT. Neuro Oncol 24(8):1286\u20131297","journal-title":"Neuro Oncol"},{"issue":"2","key":"1775_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/cancers12020308","volume":"12","author":"LS Lamb","year":"2020","unstructured":"Lamb LS, Sim HW, McCormack AI (2020) Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature-\"are we there yet?\". Cancers (Basel) 12(2):308","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1775_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1634\/theoncologist.2017-0301","volume":"23","author":"K Tzogani","year":"2018","unstructured":"Tzogani K, van Hennik P, Walsh I et al (2018) EMA review of Panobinostat (Farydak) for the treatment of adult patients with relapsed and\/or refractory multiple myeloma. Oncologist 23(5):631\u2013636","journal-title":"Oncologist"},{"issue":"7","key":"1775_CR14","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1172\/JCI129049","volume":"130","author":"TTT Nguyen","year":"2020","unstructured":"Nguyen TTT, Zhang Y, Shang E et al (2020) HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Investig 130(7):3699\u20133716","journal-title":"J Clin Investig"},{"issue":"1","key":"1775_CR15","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1038\/s41598-019-43320-5","volume":"9","author":"P Mishra","year":"2019","unstructured":"Mishra P, Paital B, Jena S et al (2019) Possible activation of NRF2 by vitamin E\/Curcumin against altered thyroid hormone induced oxidative stress via NF\u0138B\/AKT\/mTOR\/KEAP1 signalling in rat heart. Sci Rep 9(1):7408","journal-title":"Sci Rep"},{"issue":"1","key":"1775_CR16","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1038\/s41467-018-06853-3","volume":"9","author":"ZR Wu","year":"2018","unstructured":"Wu ZR, Yan L, Liu YT et al (2018) Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1\/Raptor interaction in pituitary tumours. Nat Commun 9(1):4624","journal-title":"Nat Commun"},{"issue":"9","key":"1775_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","volume":"39","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Yu HA, Yang S et al (2021) Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell 39(9):1245\u20131261","journal-title":"Cancer Cell"},{"issue":"23","key":"1775_CR18","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-20-1655","volume":"80","author":"JM Rusert","year":"2020","unstructured":"Rusert JM, Juarez EF, Brabetz S et al (2020) Functional precision medicine identifies new therapeutic candidates for medulloblastoma. Cancer Res 80(23):5393\u20135407","journal-title":"Cancer Res"},{"issue":"12","key":"1775_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1507\/endocrj.EJ15-0369","volume":"62","author":"Y Nakada","year":"2015","unstructured":"Nakada Y, Kageyama K, Sugiyama A et al (2015) Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells. Endocr J 62(12):1083\u20131090","journal-title":"Endocr J"},{"issue":"1","key":"1775_CR20","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","volume":"106","author":"D Zhang","year":"2021","unstructured":"Zhang D, Damoiseaux R, Babayan L et al (2021) Targeting corticotroph HDAC and PI3-Kinase in cushing disease. J Clin Endocrinol Metab 106(1):e232-246","journal-title":"J Clin Endocrinol Metab"},{"key":"1775_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2020.170441","volume":"136","author":"R Hagiwara","year":"2021","unstructured":"Hagiwara R, Kageyama K, Niioka K et al (2021) Involvement of histone deacetylase 1\/2 in adrenocorticotropic hormone synthesis and proliferation of corticotroph tumor AtT-20 cells. Peptides 136:170441","journal-title":"Peptides"},{"issue":"12","key":"1775_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cbin.10834","volume":"41","author":"W Wang","year":"2017","unstructured":"Wang W, Fu L, Li S et al (2017) Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells. Cell Biol Int 41(12):1290\u20131295","journal-title":"Cell Biol Int"},{"key":"1775_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.875122","volume":"12","author":"W Zhao","year":"2022","unstructured":"Zhao W, Jiang X, Weisenthal K et al (2022) High histone deacetylase 2\/3 expression in non-functioning pituitary tumors. Front Oncol 12:875122","journal-title":"Front Oncol"},{"issue":"4","key":"1775_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/10428194.2017.1359741","volume":"59","author":"B Hu","year":"2018","unstructured":"Hu B, Younes A, Westin JR et al (2018) Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):863\u2013870","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1775_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/annonc\/mdw044","volume":"27","author":"S Thomas","year":"2016","unstructured":"Thomas S, Aggarwal R, Jahan T et al (2016) A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol 27(5):947\u2013952","journal-title":"Ann Oncol"},{"issue":"519","key":"1775_CR26","doi-asserted-by":"publisher","first-page":"eaaw0064","DOI":"10.1126\/scitranslmed.aaw0064","volume":"11","author":"GL Lin","year":"2019","unstructured":"Lin GL, Wilson KM, Ceribelli M et al (2019) Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med 11(519):eaaw0064","journal-title":"Sci Transl Med"},{"issue":"11","key":"1775_CR27","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1002\/cam4.862","volume":"5","author":"N Ibrahim","year":"2016","unstructured":"Ibrahim N, Buchbinder EI, Granter SR et al (2016) A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med 5(11):3041\u20133050","journal-title":"Cancer Med"},{"issue":"15","key":"1775_CR28","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1158\/1078-0432.CCR-20-2357","volume":"27","author":"L Xiao","year":"2021","unstructured":"Xiao L, Somers K, Murray J et al (2021) Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma. Clin Cancer Res 27(15):4338\u20134352","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1775_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/cbf.3359","volume":"36","author":"YW Cheng","year":"2018","unstructured":"Cheng YW, Liao LD, Yang Q et al (2018) The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cell Biochem Funct 36(8):398\u2013407","journal-title":"Cell Biochem Funct"},{"issue":"3","key":"1775_CR30","first-page":"262","volume":"86","author":"BN Waghela","year":"2021","unstructured":"Waghela BN, Vaidya FU, Pathak C (2021) Upregulation of NOX-2 and Nrf-2 promotes 5-Fluorouracil resistance of human colon carcinoma (HCT-116) cells. Biochemistry 86(3):262\u2013274","journal-title":"Biochemistry"},{"key":"1775_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.608422","volume":"11","author":"C Dai","year":"2020","unstructured":"Dai C, Liang S, Sun B et al (2020) The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol (Lausanne) 11:608422","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1775_CR32","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1210\/jc.2017-00627","volume":"102","author":"SJ Lin","year":"2017","unstructured":"Lin SJ, Wu ZR, Cao L et al (2017) Pituitary tumor suppression by combination of cabergoline and chloroquine. J Clin Endocrinol Metab 102(10):3692\u20133703","journal-title":"J Clin Endocrinol Metab"},{"key":"1775_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.955100","volume":"13","author":"S Lin","year":"2022","unstructured":"Lin S, Han C, Lou X et al (2022) Hydroxychloroquine overcomes cabergoline resistance in a patient with lactotroph pituitary neuroendocrine tumor: a case report. Front Endocrinol 13:955100","journal-title":"Front Endocrinol"},{"issue":"11","key":"1775_CR34","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A, Venkannagari S, Oh KH et al (2016) Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol 11(11):3214\u20133225","journal-title":"ACS Chem Biol"},{"key":"1775_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.freeradbiomed.2021.04.006","volume":"169","author":"S Qin","year":"2021","unstructured":"Qin S, He X, Lin H et al (2021) Nrf2 inhibition sensitizes breast cancer stem cells to ionizing radiation via suppressing DNA repair. Free Radic Biol Med 169:238\u2013247","journal-title":"Free Radic Biol Med"},{"key":"1775_CR36","first-page":"6616547","volume":"2021","author":"H Liu","year":"2021","unstructured":"Liu H, Xu X, Wu R et al (2021) Antioral squamous cell carcinoma effects of carvacrol via inhibiting inflammation, proliferation, and migration related to Nrf2\/Keap1 pathway. Biomed Res Int 2021:6616547","journal-title":"Biomed Res Int"},{"key":"1775_CR37","first-page":"4182401","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Xin Z, Dong B et al (2022) Combination of the NRF2 inhibitor and autophagy inhibitor significantly inhibited tumorigenicity of castration-resistant prostate cancer. Comput Math Methods Med 2022:4182401","journal-title":"Comput Math Methods Med"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-024-01775-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:28:32Z","timestamp":1713436112000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-024-01775-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1186\/s40478-024-01775-2","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}